Rekombinanter Abatacept Biosimilar Antikörper

Produktnummer ABIN7795080

Der Maus Monoklonal anti-Abatacept Biosimilar Antikörper wird verwendet zum Nachweis von Abatacept Biosimilar in Proben von Human. Er wurde validiert für FACS und in vivo.

Kurzübersicht für Rekombinanter Abatacept Biosimilar Antikörper (ABIN7795080)

Target: Abatacept Biosimilar

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails

Expressionssystem: Mammalian cells

Verwendungszweck: Abatacept Biosimilar

Spezifität: The abatacept biosimilar protein specifically binds to the human CD80 (B7-1) with more avidity than to CD86 (B7-2).

Produktmerkmale: Abatacept (trade name Orencia, Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Abatacept binds to CD80 (B7-1) with more avidity than to CD86 (B7-2). Abatacept inhibits the costimulation of T cells. Abatacept differs from belatacept (trade name Nulojix) by only 2 amino acids. The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Antigendetails

Target: Abatacept Biosimilar

Substanzklasse: Biosimilar